{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.904","upperLimit":"1.07","value":"0.984"}]}],"title":"Platinum in plasma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.940","upperLimit":"1.32","value":"1.11"}]}],"title":"Platinum in ultrafiltrate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Cmax was observed directly from data. Oxaliplatin was evaluated as total platinum in plasma and platinum in plasma ultrafiltrate. The ratio between geometric LS mean (within Cohort 2) for Cmax on Cycle 1 Day 15 and geometric LS mean (within Cohort 2) for Cmax on Cycle 1 Day 1 for Oxaliplatin has been presented in this outcome measure, which explains the data reported for this outcome measure using measure type as \"Number\".","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"NUMBER","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants received oxaliplatin in Cohort 2 of SLI, hence data is reported only for Cohort 2 and not for Cohort 1.","reportingStatus":"POSTED","timeFrame":"Cohort 2: Pre-dose (0 hr), 1, 2, 3, 4, 6, 8, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI, Cohort 2: Ratio of Cmax on Cycle 1 Day 15 as Compared to Cycle 1 Day 1 for Oxaliplatin","type":"SECONDARY","unitOfMeasure":"Ratio"}